We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MicroRNA Profiling Shows Promise as Diagnostic and Prognostic Tool for Bladder Cancer

By LabMedica International staff writers
Posted on 28 Aug 2013
Profiling of 15 microRNAs (miRNAs) from bladder tissue showed with 100% accuracy whether the cells were normal or malignant, while the determination of only two miRNAs could predict how well the patient would be able to defend against bladder cancer.

Bladder cancer is a common cancer in the Western world. More...
However, the current prognosticators such as tumor grade, stage, size, and multifocality do not accurately reflect the clinical outcome. In about three-quarters of bladder cancer patients the tumors are confined to the mucosa or submucosa (non-muscle invasive bladder cancer, NMIBC), whereas in the rest of the cases the cancers have already invaded nearby muscle (muscle-invasive bladder cancer, MIBC).

Investigators at University Hospital Charité (Berlin, Germany) turned to the profiling of microRNAs from bladder tissue as a better way to detect cancer and predict how it would likely grow and spread. MicroRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

The investigators screened 723 miRNAs by microarray and selected a subset of 15 distinctively deregulated miRNAs for further validation by real-time quantitative RT-(q)PCR. Seven miRNAs were found to be up-regulated and eight miRNAs were found to be down-regulated in malignant bladder tissue samples compared to healthy tissue. Four miRNAs that had already been described in the literature (miR-141, miR-199a-3p, miR-205, and miR-214) were significantly differentially expressed between non-muscle-invasive and muscle-invasive bladder cancer.

When all 15 of the selected miRNAs were considered together, they correctly classified 100% of tissues as either normal or malignant, and two miRNAs (miR-141 and miR-205) significantly correlated with survival.

"These results underline the great potential of miRNAs to serve as diagnostic markers, as previously noted for other urological tumors," said senior author Dr. Klaus Jung, professor of urology at the University Hospital Charité. "These findings could be of clinical importance, but these results must be interpreted cautiously. However, previously published studies underline the possible prognostic potential of miRNAs to predict progression and disease-specific or overall survival in bladder cancer patients."

The study demonstrating the usefulness of miRNA profiling for diagnosis and prognosis of bladder cancer was published in the August 14, 2013, online edition of the Journal of Molecular Diagnostics.

Related Links:
University Hospital Charité




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.